Navigation Links
Interleukin Genetics Announces Conference Call to Discuss Fourth Quarter 2008 Results
Date:2/27/2009

WALTHAM, Mass., Feb. 27 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Alternext US: ILI) announced today that it will host a conference call and Webcast on Monday, March 9, 2009, at 4:30 p.m. EDT to review the Company's fourth quarter and year end 2008 financial results, and provide an update on recent corporate developments.

To access the live call, dial 877-795-3646 (domestic) or 719-325-4833 (international). The live Webcast and replay access of the teleconference will be available on the Investors section of the Company's Website at http://www.ilgenetics.com.

Interleukin Genetics, Inc. (NYSE Alternext US: ILI), is a healthcare company that specializes in the development of genetic biomarker tests for sale to the emerging personalized health market. The Company is focused on the future of health and medicine. Interleukin Genetics uses its leading genetics research and scientific capabilities to develop and commercialize innovative diagnostic and risk assessment genetic tests. These products could help to improve an individual's understanding of needed lifestyle changes or of therapeutic products that can be used to better manage their health. Interleukin Genetics has developed and commercialized genetic tests for risk assessment of coronary artery disease, periodontal disease, and general nutrition. Through its AJG subsidiary, the Company also currently offers an array of Nutraceutical and OTCeuticals(R) products, including Ginkoba(TM), Ginsana(R) and Venastat(R) which are sold at the nation's largest food, drug and mass retailers. Interleukin Genetics is headquartered in Waltham, MA. For more information about Interleukin Genetics and its ongoing programs, please visit www.ilgenetics.com.


'/>"/>
SOURCE Interleukin Genetics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Interleukin Genetics to Present at G-2 Reports Molecular Diagnostic Conference
2. Interleukin Genetics Submits Plan to Regain Compliance with Continued Listing Standards
3. Interleukin Genetics to Present Data Highlighting Link Between Inflammatory Gene Variations and Less Effective Weightloss
4. Novel bioreactor enhances interleukin-12 production in genetically-modified tobacco plants
5. Interleukin Genetics Announces Conference Call and Webcast to Discuss Third Quarter 2008 Business Results
6. Interleukin Genetics to Present at Rodman & Renshaw 10th Annual Healthcare Conference
7. Interleukin-12 indicates survival prospects for melanoma patients
8. LaVoie Group Adds Interleukin Genetics to its Life Science Agency Roster
9. Interleukin Genetics Reports Fourth Quarter and Year End 2007 Financial Results
10. T cell immunity enhanced by timing of interleukin-7 therapy
11. Interleukin Genetics, Inc. Management to Present at Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... 2016 , ... The Wickman Agency in Garland, TX has ... community. Pledging to select a new beneficiary every 60 days, the agency will ... is to bring community awareness to important local causes by forming campaigns which ...
(Date:2/10/2016)... ... February 10, 2016 , ... Dr. Peyman Ghasri, skin ... a variety of comprehensive procedures for facial enhancement. The treatments now available at ... enhancement and nasal reshaping. , As a result, patients can improve virtually ...
(Date:2/10/2016)... ... February 10, 2016 , ... Intalere’s ... together more than 200 of the country’s top healthcare executives to share insights ... true benefit of the Forum is the provider-centric perspective, experience, expertise and strategy ...
(Date:2/10/2016)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral ... December 31, 2015 on Monday, February 29, 2016 after the market closes. , The ... release at 4:30 PM ET. Investors interested in participating by phone are invited to ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists ... their patients. Research shows that the Goal Attainment Scale (GAS) captures 20% more ... challenge and learn more about the Goal Attainment Scale, Education Resources Inc. is ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... Feb. 9, 2016 On Tuesday, ... (FDA) met with its Arthritis Advisory Committee ... of Johnson & Johnson,s Remicade and most ... in the U.S. The Biologics Prescribers Collaborative ... - Alliance for Patient Access, American Association ...
(Date:2/10/2016)... 2016 Demonstrates changes in ... receptor selectivity   1 receptor ... entered clinical development as a new treatment for ...   --> 1 receptor agonist, ... clinical development as a new treatment for cognitive ...
(Date:2/9/2016)... Corporation (NASDAQ: PODD ) (Insulet or the Company), the ... OmniPod ® Insulin Management System, today announced ... Insulet,s Board of Directors. With his appointment, the Board is ... --> --> Mr. Lemoine ... a deep knowledge of accounting, financial reporting and internal controls ...
Breaking Medicine Technology: